Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
At ChiroHer, we are committed to providing personalized care
doi: 10.1111/liv.13480
Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes
